Zoetis Inc. (ZTS) Debt to Equity Ratio: 2.85
Is Zoetis Inc.’s debt to equity ratio high or low?
Zoetis Inc.'s debt to equity ratio of 2.85 is 57% above its 5-year average of 1.81, near the high end of its 5-year range (1.35–2.85).
The debt to equity ratio for Zoetis Inc. (ZTS) is 2.85 as of Tuesday, June 9, 2026. It is above its 12-month average by 33.80% (2.13).
ZTS Debt to Equity Ratio Chart
ZTS Average Debt to Equity Ratio Chart
ZTS Current vs Average Debt to Equity Ratio Chart
ZTS Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
2.85
DEBT TO EQUITY RATIO AVG TTM
2.13
DEBT TO EQUITY RATIO AVG 3Y
1.86
DEBT TO EQUITY RATIO AVG 5Y
1.81
DEBT TO EQUITY RATIO AVG 10Y
2.42
DEBT TO EQUITY RATIO AVG 15Y
2.11
DEBT TO EQUITY RATIO AVG 20Y
1.99
CURRENT VS TTM AVG
+33.80%
CURRENT VS 3Y AVG
+53.02%
CURRENT VS 5Y AVG
+57.17%
CURRENT VS 10Y AVG
+17.72%
CURRENT VS 15Y AVG
+34.95%
CURRENT VS 20Y AVG
+43.39%
ZTS Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | — | 2.85 | 2.13 | 1.86 | 1.81 |
| Centene Corporation (CNC) | $32.69B | 0.94 | 0.84 | 0.83 | 0.81 |
| IQVIA Holdings Inc. (IQV) | $31.09B | 2.49 | 2.41 | 2.34 | 2.26 |
| Agilent Technologies, Inc. (A) | $38.26B | 0.50 | 0.55 | 0.53 | 0.52 |
| DexCom, Inc. (DXCM) | $30.17B | 0.51 | 0.87 | 1.00 | 1.01 |
| Biogen Inc. (BIIB) | $29.39B | 0.38 | 0.39 | 0.44 | 0.53 |
| Veeva Systems Inc. (VEEV) | $27.37B | 0.01 | 0.01 | 0.01 | 0.02 |
| Humana Inc. (HUM) | $43.60B | 0.73 | 0.74 | 0.75 | 0.72 |
| Waters Corporation (WAT) | $24.19B | 0.58 | 0.76 | 1.73 | 2.93 |
| Mettler-Toledo International Inc. (MTD) | $23.50B | -99.14 | 48.23 | 26.06 | 17.96 |
Financial Health
Debt/Equity
2.85
Current Ratio
3.03
Zoetis Inc. Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Zoetis Inc. (ZTS)?
- The debt to equity ratio for ZTS stock is 2.85.
- Is Zoetis Inc.'s debt to equity ratio high or low?
- Zoetis Inc.'s debt to equity ratio of 2.85 is 57% above its 5-year average of 1.81, near the high end of its 5-year range (1.35–2.85).
- What is the TTM average debt to equity ratio for Zoetis Inc. (ZTS)?
- The TTM average debt to equity ratio for ZTS stock is 2.13.
- What is the 3Y average debt to equity ratio for Zoetis Inc. (ZTS)?
- The 3Y average debt to equity ratio for ZTS stock is 1.86.
- What is the 5Y average debt to equity ratio for Zoetis Inc. (ZTS)?
- The 5Y average debt to equity ratio for ZTS stock is 1.81.
- What is the 10Y average debt to equity ratio for Zoetis Inc. (ZTS)?
- The 10Y average debt to equity ratio for ZTS stock is 2.42.
- What is the 15Y average debt to equity ratio for Zoetis Inc. (ZTS)?
- The 15Y average debt to equity ratio for ZTS stock is 2.11.
- What is the 20Y average debt to equity ratio for Zoetis Inc. (ZTS)?
- The 20Y average debt to equity ratio for ZTS stock is 1.99.
Zoetis Inc. Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 2.85 |
| 2024-12-31 | 1.41 |
| 2023-12-31 | 1.35 |
| 2022-12-31 | 1.84 |
| 2021-12-31 | 1.48 |
| 2020-12-31 | 1.95 |
| 2019-12-31 | 2.44 |
| 2018-12-31 | 2.95 |
| 2017-12-31 | 2.80 |
| 2016-12-31 | 3.00 |
| 2015-12-31 | 4.56 |
| 2014-12-31 | 2.77 |
| 2013-12-31 | 3.89 |
| 2012-12-31 | 0.14 |
| 2011-12-31 | 0.15 |
| 2010-12-31 | 0.21 |
| 2009-12-31 | 0.00 |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck